Хірургічне втручання у пацієнтів, які проходять антитромбоцитарну терапію 10 страница

782. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ,­Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A, Intracoronary S, Antithrombotic­Regimen-Rapid Early Action for Coronary Treatment Study I. A clinical­trial of abciximab in elective percutaneous coronary intervention after pretreatment­with clopidogrel. N Engl J Med 2004;350(3):232–238

783. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ,­Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A,­DesmetW, RutschW, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Long-term­efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs.heparin and­planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization:­REPLACE-2 randomized trial. JAMA 2004;292(6):696–703

784. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA,­Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA,­Dirschinger J, Richardt G, Berger PB, Schomig A, Investigators I-RT. Bivalirudin­vs. unfractionated heparin during percutaneous coronary intervention. N Engl J­Med 2008;359(7):688–696

785. Ndrepepa G, Schulz S, Keta D, Mehilli J, Birkmeier A, Massberg S, Laugwitz K,­Neumann F, Seyfarth M, Berger P, Scho¨mig A, Kastrati A. Bleeding after percutaneous­coronary intervention with Bivalirudin or unfractionated Heparin and­one-year mortality. Am J Cardiol 2010;105(2):163–167

786. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C,­Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 2006;355(10):1006–1017

787. Montalescot G, Gallo R, White HD, Cohen M, Steg PG, Aylward PE, Bode C,­Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention­1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous­coronary intervention patients, an international randomized evaluation)­trial. JACC Cardiovasc Interv 2009;2(11):1083–1091

788. Silvain J, Beygui F, Barthe´le´my O, Pollack C Jr., Cohen M, Zeymer U, Huber K,­Goldstein P, Cayla G, Collet J-P, Vicaut E, Montalescot G. Efficacy and safety of­enoxaparin vs. unfractionated heparin during percutaneous coronary intervention:­systematic review and meta-analysis. BMJ 2012;344

789. Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A. Effectiveness of­in-laboratory high-dose clopidogrel loading vs. routine pre-load in patients undergoing­percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD­(Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty)­randomized trial. J Am Coll Cardiol 2010;56(7):550–557

790. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG,­Slama M, Milleron O, Collet JP,Henry P, Beygui F, Drouet L.Arandomized comparison­of high clopidogrel loading doses in patients with non-ST-segment elevation­acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose­of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis)­trial. J Am Coll Cardiol 2006;48(5):931–938

791. Steinhubl SR, Berger S, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ, for the­Credo I. Early and sustained dual oral antiplatelet therapy following percutaneous­coronary intervention. JAMA 2002;288:2411–2418

792. Widimsky P, Motovska Z, Simek S, Kala P, Pudil R, Holm F, Petr R, Bilkova D,­Skalicka H, Kuchynka P, Poloczek M, Miklik R, Maly M, Aschermann M. Clopidogrel­pre-treatment in stable angina: for all patients.6 h before elective coronary angiography­or only for angiographically selected patients a few minutes before PCI? A­randomized multicentre trial PRAGUE-8. Eur Heart J 2008;29(12):1495–1503

793. Collaborative overview of randomised trials of antiplatelet therapy:I: Prevention of­death, myocardial infarction, and stroke by prolonged antiplatelet therapy in­various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ (Clinical research­ed.) 1994;308(6921):81–106

794. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J,­Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A Aspirin in the primary and secondary prevention of vascular disease: collaborative­meta-analysis of individual participant data from randomised trials. Lancet 2009;­373(9678):1849–1860

795. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the­safety of clopidogrel with and without a loading dose in combination with aspirin­compared with ticlopidine in combination with aspirin after coronary stenting:­the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation­2000;102(6):624–629

796. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel­after intracoronary stent implantation in a broad patient population. Circulation­2001;104(5):539–543

797. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel­and aspirin vs. ticlopidine and aspirin after the placement of coronary-artery­stents. Circulation 2000;101(6):590–593

798. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900 mg­loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting­and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate­Clopidogrel Effect) Trial. Circulation 2005;112(19):2946–2950

799. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F,­Colombo F, Tebaldi M, Fuca` G, Kubbajeh Md, Cangiano E, Minarelli M,­Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G,­Ferrari R. Short- vs. long-term duration of dual-antiplatelet therapy after coronary­stenting: a randomized multicenter trial. Circulation 2012;125(16):2015–2026

800. Scho¨mig A,NeumannFJ, Kastrati A, Schu¨hlen H, Blasini R, Hadamitzky M,Walter H,­Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K.Arandomized comparison­of antiplatelet and anticoagulant therapy after the placement of coronary-artery­stents. N Engl J Med 1996;334(17):1084–1089

801. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A,­Diver DJ, Lasorda DM, WilliamsDO, Pocock SJ, Kuntz RE.Aclinical trial comparing­three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation­Restenosis Study Investigators. N Engl J Med 1998;339(23):1665–1671

802. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual­antiplatelet therapy after percutaneous coronary interventions in the drug-eluting­stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33(24):3078–3087

803. GwonHC,Hahn JY, ParkKW, Song YB, Chae IH, Lim DS, HanKR, Choi JH, Choi SH,­Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, ChungWY, Choi YJ, Hur SH,­Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Sixmonth­vs. 12-month dual antiplatelet therapy after implantation of drug-eluting­stents: the Efficacy of Xience/Promus Vs. Cypher to Reduce Late Loss After Stenting­(EXCELLENT) randomized, multicenter study. Circulation 2012;125(3):­505–513

804. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB,­Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela E,­Perin MA, Devito FS, Labrunie A, Salvadori D, Gusma˜o M, Staico R, Costa JR, de­Castro JP, Abizaid AS, Bhatt DL. Three vs.Twelve Months of Dual Antiplatelet­Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial JAMA 2013;310(23):2510–2522

805. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE,­KangWC,Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y.Anew strategy for discontinuation­of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of­3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent­implantation). J Am Coll Cardiol 2012;60(15):1340–1348

806. Schulz S, Mehilli J,NeumannFJ, SchusterT, Massberg S, Valina C, Seyfarth M, Pache J,­Laugwitz KL, Buttner HJ, Ndrepepa G, Schomig A, Kastrati A. ISAR-REACT 3A: a­study of reduced dose of unfractionated heparin in biomarker negative patients­undergoing percutaneous coronary intervention. Eur Heart J 2010;31(20):­2482–2491

807. Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet JP,­Steinhubl SR, Montalescot G. Intravenous low-molecular-weight heparins compared­with unfractionated heparin in percutaneous coronary intervention: quantitative­review of randomized trials. Arch Intern Med 2007;167(22):2423–2430

808. Mehran R, Pocock SJ, StoneGWet al. Associations of major bleeding and myocardial­infarction with the incidence and timing of mortality in patients presenting with­non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial Eur Heart J 2009;30:1457–1466

809. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY,­Gibler WB, Ohman EM, Roe MT, Pollack CV Jr., Peterson ED, Alexander KP. Baseline­risk of major bleeding in non-ST-segment-elevation myocardial infarction: the­CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress­ADverse outcomes with Early implementation of the ACC/AHA Guidelines)­Bleeding Score. Circulation 2009;119(14):1873–1882

810. Pena A, Collet JP, Hulot JS, Silvain J, Barthe´le´my O, Beygui F, Funck-Brentano C,­Gilles M. Can we override clopidogrel resistance? Circulation 2009;119(21):­2854–2858

811. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG,­Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC,­Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL,­Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR,­Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M,­McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K,­Hochman JS, Ohman EM. Prasugrel vs. clopidogrel for acute coronary syndromes­without revascularization. N Engl J Med 2012;367(14):1297–1309

812. Mehta S, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP,­Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP,­Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD,­Chrolavicius S, Gao P, Fox KAA, Yusuf S, on behalf of the CI. Double-dose vs standard-dose clopidogrel and high-dose vs. low-dose aspirin in individuals undergoing­percutaneous coronary intervention for acute coronary syndromes­(CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233–1243

813. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van deWerf F, de­Torbal A, Armstrong PW,Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ,­SimoonsML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a­meta-analysis of all major randomised clinical trials. Lancet 2002;359(9302):­189–198

814. Kastrati A, Mehilli J, Neumann F-J, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M,­Pache J, Seyfarth M, Schu¨hlen H, Dirschinger J, Berger PB, Scho¨mig A. Abciximab in­patients with acute coronary syndromes undergoing percutaneous coronary intervention­after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA­2006;295(13):1531–1538

815. StoneGW,McLaurinBT,CoxDA, Bertrand ME, Lincoff AM, MosesJW, WhiteHD,­Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H,­Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J,­Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes N Engl J Med 2006;355(21):2203–2216

816. StoneGW,Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD,­Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC,­Mehran R, Pocock SJ. Antithrombotic strategies in patients with acute coronary­syndromes undergoing early invasive management: one-year results from the­ACUITY trial. JAMA 2007;298(21):2497–2506

817. Kastrati A, Neumann F-J, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz K-L,­Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Scho¨mig A, Berger PB,­Mehilli J. Abciximab and heparin vs. bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 2011;365(21):1980–1989

818. O’Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A,­Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efficacy safety­of prasugrel with without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary­syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial­to Assess Improvement in Therapeutic utcomes by Optimizing Platelet Inhibition­With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll­Cardiol 2009;54(8):678–685

819. Cohen M, Mahaffey KW, Pieper K, Pollack CV Jr., Antman EM, Hoekstra J,­Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ. A subgroup analysis­of the impact of prerandomization antithrombin therapy on outcomes in the­SYNERGY trial: enoxaparin vs. unfractionated heparin in non-ST-segment elevation­acute coronary syndromes. J Am Coll Cardiol 2006;48(7):1346–1354

820. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ,­Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P,­Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S,­Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL,­Pepine CJ, RuzylloW, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H. Enoxaparin­vs.unfractionated heparin in high-risk patients with non-ST-segment elevation­acute coronary syndromes managed with an intended early invasive­strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292(1):­45–54

821. Kastrati A, Neumann F-J, Mehilli J, Byrne RA, Iijima R, Bu¨ttner HJ, Khattab AA,­Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA,­Dirschinger J, Richardt G, Berger PB, Scho¨mig A. Bivalirudin vs. unfractionated­heparin during percutaneous coronary intervention. N Engl J Med 2008;359(7):­688–696

822. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S,­Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG,­Bassand J-P, Wallentin L, Joyner C, Fox KAA. Comparison of fondaparinux and­enoxaparin in acute coronary syndromes. N Engl J Med 2006;354(14):1464–1476

823. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP,­Emanuelsson H, Finkelstein A HS, Katus H, Kilhamn J, Olofsson S, Storey RF,­Weaver WD, Wallentin L, for the PSG. Ticagrelor Vs. Clopidogrel in Patients­With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With­Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient­Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010;122(21):­2131–2141

824. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De­Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin­prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial­infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B­trial. Circulation 1999;100(15):1593–1601

825. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K,­Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment­with clopidogrel and aspirin followed by long-term therapy in patients undergoing­percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;­358(9281):527–533

826. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J-F, Ten­Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J,­Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E,­Widimsky P, the AI. Pretreatment with Prasugrel in Non-ST-Segment Elevation­Acute Coronary Syndromes. N Engl J Med 2013;369(11):999–1010

827. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL,­Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B,­Joyner C, Pogue J, Yusuf S. Low-dose vs.standard-dose unfractionated heparin for­percutaneous coronary intervention in acute coronary syndromes treated with­fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010;304(12):­1339–1349

828. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH,­Antman EM, investigators T-T. Prasugrel compared with clopidogrel in patients­undergoing percutaneous coronary intervention for ST-elevation myocardial infarction­(TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet­2009;373(9665):723–731

829. Erlinge D, Ten Berg J, Foley D, Angiolillo DJ,Wagner H, Brown PB, Zhou C, Luo J,­Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ. Reduction in­platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to­prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J­Am Coll Cardiol 2012;60(20):2032–2040

830. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, Barthe´le´my O,­Collet JP, Montalescot G. New P2Y12 inhibitors vs. clopidogrel in percutaneous­coronary intervention: a meta-analysis. J Am Coll Cardiol. 2010;56(19):1542–1551

831. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors­among patients with ST-segment elevation myocardial infarction treated with­primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J­2009;30:2705–2713

832. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P,­Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P. Platelet glycoprotein­IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N­Engl J Med 2001;344(25):1895–1903

833. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP,­Schmitt C, Seyfarth M, Dirschinger J, Schomig A. Evaluation of prolonged antithrombotic­pretreatment ("cooling-off" strategy) before intervention in patients­with unstable coronary syndromes: a randomized controlled trial. JAMA 2003;­290(12):1593–1599

834. Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A,­Neuman F-J, Effron MB, Barnathan ES, Topol EJ, Ellis SG, Investigators F. Benefit­of facilitated percutaneous coronary intervention in high-risk ST-segment elevation­myocardial infarction patients presenting to nonpercutaneous coronary intervention­hospitals. JACC Cardiovascular Interventions 2009;2(10):917–924

835. Van’t Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W,­Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P,­Giannitsis E, Hamm C, Ongoing Tirofiban In Myocardial infarction Evaluation 2­study g. Prehospital initiation of tirofiban in patients with ST-elevation myocardial­infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind,­randomised controlled trial. Lancet 2008;372(9638):537–546

836. en Berg JM, van ’t HofAW, Dill T, Heestermans T, vanWerkum JW, Mosterd A, van­Houwelingen G, Koopmans PC, Stella PR, Boersma E,HammC. Effect of early, prehospital­initiation of high bolus dose tirofiban in patients with ST-segment elevation­myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol­2010;55(22):2446–2455

837. Montalescot G. Mechanical reperfusion: treat well, treat on time too. Lancet 2008;­372(9638):509–510

838. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH,­Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S,­El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R,­Gibson CM. Intracoronary abciximab and aspiration thrombectomy in patients­with large anterior myocardial infarction: the INFUSE-AMI randomized trial JAMA 2012;307(17):1817–1826

839. Thiele H, Wo¨ hrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P,­Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S,­Schuler G. Intracoronary vs. intravenous bolus abciximab during primary percutaneous­coronary intervention in patients with acute ST-elevation myocardial infarction:­a randomise trial. Lancet 2012;379(9819):923–931

840. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,­Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G,Wong SC, Kirtane AJ,­Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 2008;358(21):2218–2230

841. Steg PG, van ’t HofAW,HammCW, Clemmensen P, Lapostolle F, Coste P, Berg JT,­Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Orto MC, Nef H, Steinmetz J,­Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton TC,­Pocock SJ, Hamon M, Goldstein P. Bivalirudin Started during Emergency Transport­for Primary PCI. N Engl J Med 2013;369(23):2207–2217

842. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C,­Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S,­Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH; for the HEAT-PPCI­trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous­coronary intervention (HEAT-PPCI): an open-label, single centre, randomised­controlled trial. Lancet 2014.doi: 10.1016/S0140-6736(14)60924-7

843. Richardt G. Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial. Eur­Heart J. Published online 9 May 2014; doi: 10.1093/eurheartj/ehu182

844. Collet J-P, Huber K, Cohen M, Zeymer U, Goldstein P, Pollack C Jr., Silvain J,­Henry P, Varenne O, Carrie´ D, Coste P, Angioi M, Le Breton H, Cayla G,­Elhadad S, Teiger E, Filippi E, Aout M, Vicaut E, Montalescot G, Investigators A. A­Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in­Primary Percutaneous Coronary Intervention (from the ATOLL Trial). Am J­Cardiol 2013;112(9):1367–1372

845. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ,­Bassand JP,Wallentin L, Joyner C, Fox KA. Effects of fondaparinux on mortality and­reinfarction in patients with acute ST-segment elevation myocardial infarction: the­OASIS-6 randomized trial. JAMA 2006;295(13):1519–1530

846. Zeymer U, Arntz HR, Mark B, Fichtlscherer S, Werner G, Scholler R, Zahn R,­Diller F, Darius H, Dill T, Huber K. Efficacy and safety of a high loading dose of clopidogrel­administered prehospitally to improve primary percutaneous coronary­intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res­Cardiol 2012;101(4):305–312

847. Koul S, Smith JG, Schersten F, James S, Lagerqvist B, Erlinge D. Effect of upstream­clopidogrel treatment in patients with ST-segment elevation myocardial infarction­undergoing primary percutaneous coronary intervention. Eur Heart J 2011;32(23):­2989–2997

848. Dorler J, Edlinger M, Alber HF, Altenberger J, Benzer W, Grimm G, Huber K,­Pachinger O, Schuchlenz H, Siostrzonek P, Zenker G, Weidinger F. Clopidogrel­pre-treatment is associated with reduced in-hospital mortality in primary percutaneous­coronary intervention for acute ST-elevation myocardial infarction. Eur Heart­J 2011;32(23):2954–2961

849. De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M,­Gabriel HM, Zorman S, De Carlo M, Rakowski T, Gyongyosi M, Dudek D. Early­glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results­(EGYPT-ALT) cooperation: individual patient’s data meta-analysis. Journal of Thrombosis­and Haemostasis: JTH 2011;9(12):2361–2370

850. Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P,­Margenet A, Huber K, Pollack C, Be´nezet JF, Stibbe O, Filippi E, Teiger E, Cayla G,­Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E, for­the AI. Intravenous Enoxaparin or Unfractionated Heparin in Primary Percutaneous­Coronary Intervention for ST-Elevation Myocardial Infarction. Lancet 2011;­378(9792):693–703

851. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL,­Sapp SK,Wolski K, Bhatt DL, Topol EJ. Triple antiplatelet therapy during percutaneous­coronary intervention is associated with improved outcomes including­one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy­Outcome Trial (TARGET). J Am Coll Cardiol 2003;42(7):1188–1195

852. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ,­Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky´ P, Tousek F, Tauth J,­Spriggs D, McLaurin BT, Angiolillo DJ, Ge´ne´reux P, Liu T, Prats J, Todd M,­Skerjanec S, White HD, Harrington RA. Effect of Platelet Inhibition with Cangrelor­during PCI on Ischemic Events. N Engl J Med 2013;368(14):1303–1313

853. Steg PG, Bhatt DL, HammCW, StoneGW, Gibson CM, MahaffeyKW, Leonardi S,­Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, GogiaHS, Gruberg L, French WJ,­White HD, Harrington RA. Effect of cangrelor on periprocedural outcomes in percutaneous­coronary interventions: a pooled analysis of patient-level data. Lancet­2013;382(9919):1981–1992

854. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ,­Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T,­Montalescot G, Manoukian SV, Prats J, Topol EJ. Bridging antiplatelet therapy­with cangrelor in patients undergoing cardiac surgery: a randomized controlled­trial. JAMA 2012;307(3):265–274

855. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,­Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,­Schneider D, Sun X, Verheugt FW, Gibson CM, the AACSTI. Rivaroxaban in­Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366:9–19

856. Gibson CM,Chakrabarti AK, Mega J, Bode C, Bassand J-P, VerheugtFWA, Bhatt DL,­Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E,­Investigators A-AT. Reduction of Stent Thrombosis in Patients With Acute Coronary­Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll­Cardiol 2013;62(4):286–290

857. Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG,­Parkhomenko A, Tendera M, Widimsky P, Gibson CM. Rivaroxaban in patients stabilized­after a ST-segment elevation myocardial infarction: results from the ATLAS­ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition­to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In­Myocardial Infarction-51). J Am Coll Cardiol 2013;61(18):1853–1859

858. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S,­Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De­Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D,­Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R,­White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L,­Investigators A-. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med. 2011;365(8):699–708

859. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JGP, Van de­Werf F, Wallentin L. Dabigatran vs. placebo in patients with acute coronary syndromes­on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 2011;32(22):2781–2789

860. Steg PG, Mehta SR, Jukema JW, Lip GYH, Gibson CM, Kovar F, Kala P,­Garcia-Hernandez A, Renfurm RW, Granger CB. RUBY-1: a randomized, doubleblind,­placebo-controlled trial of the safety and tolerability of the novel oral factor­Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J­2011;32(20):2541–2554

861. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA,­Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J,­Mohan P, Montalescot G, Ruda M, RuzylloW, Verheugt F,Wallentin L. Apixaban,­an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet­therapy after acute coronary syndrome: results of the Apixaban for Prevention­of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):­2877–2885

862. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V,­Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban­vs. placebo in patients with acute coronarysyndromes (ATLASACS-TIMI­46): a randomised, double-blind, phase II trial. Lancet 2009;374(9683):29–38

863. Ruiz-Nodar JM, Marı´n F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR,­Sogorb F, Valde´s M, Lip GYH. Anticoagulant and antiplatelet therapy use in 426­patients with atrial fibrillation undergoing percutaneous coronary intervention­and stent implantation implications for bleeding risk and prognosis. J Am Coll­Cardiol 2008;51(8):818–825

864. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N,­Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE,­Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy­with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Archives of­Internal Medicine 2010;170(16):1433–1441

Не нашли, что искали? Воспользуйтесь поиском: